BioCentury
ARTICLE | Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

How Tmunity’s focus on CMC for its engineered T cell therapies factored into its $75M series B

November 1, 2019 12:06 AM UTC
Updated on Nov 5, 2019 at 11:25 PM UTC

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors.

Andreessen Horowitz (a16z) led the financing, which saw participation from existing investor Westlake Village BioPartners...